References
1. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol . Mar 2022;17(3):362-387. doi:10.1016/j.jtho.2021.11.003
2. Sun L, Dai J, Chen Y, et al. Pulmonary Sarcomatoid Carcinoma: Experience From SEER Database and Shanghai Pulmonary Hospital. Ann Thorac Surg . Aug 2020;110(2):406-413. doi:10.1016/j.athoracsur.2020.02.071
3. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery . Sep 2012;152(3):397-402. doi:10.1016/j.surg.2012.05.007
4. Zhu J, Yuan Y, Wan X, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev . Dec 6 2021;12:CD011300. doi:10.1002/14651858.CD011300.pub3
5. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol . Dec 2013;8(12):1574-7. doi:10.1097/01.JTO.0000437008.00554.90
6. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med . Aug 13 2020;383(7):640-649. doi:10.1056/NEJMoa1916623
7. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med . Mar 2020;41(1):1-24. doi:10.1016/j.ccm.2019.10.001
8. Steuer CE, Behera M, Liu Y, et al. Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clin Lung Cancer . May 2017;18(3):286-292. doi:10.1016/j.cllc.2016.11.016
9. Arabiat M, Bhat P, Steff R, Singh K. A 56-Year-Old Woman With Nonresolving Pneumonia. Chest . Oct 2021;160(4):e369-e370. doi:10.1016/j.chest.2020.10.097
10. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med . Aug 2021;27(8):1345-1356. doi:10.1038/s41591-021-01450-2
11. Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw . Dec 2019;17(12):1464-1472. doi:10.6004/jnccn.2019.0059
12. Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ . Nov 9 2021;375:n2363. doi:10.1136/bmj.n2363
13. Socinski MA, Obasaju C, Gandara D, et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol . Feb 2018;13(2):165-183. doi:10.1016/j.jtho.2017.11.111
14. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol . Sep 2015;10(9):1243-1260. doi:10.1097/JTO.0000000000000630
15. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med . Feb 2012;136(2):163-71. doi:10.5858/arpa.2011-0320-OA
16. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol . Feb 2005;29(2):179-87. doi:10.1097/01.pas.0000149690.75462.29
17. Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Buttner R. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol . Sep 2022;84:184-198. doi:10.1016/j.semcancer.2020.07.009
18. Lebow ES, Murciano-Goroff YR, Brannon AR, et al. MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA. Journal of Clinical Oncology . 2020;38(15_suppl):3529-3529. doi:10.1200/JCO.2020.38.15_suppl.3529
19. Lococo F, Torricelli F, Rossi G, et al. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. Lung Cancer . Nov 2017;113:93-101. doi:10.1016/j.lungcan.2017.09.009
20. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol . Apr 2020;15(4):499-519. doi:10.1016/j.jtho.2019.12.107
21. Sezer A, Kilickap S, Gumus M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet . Feb 13 2021;397(10274):592-604. doi:10.1016/S0140-6736(21)00228-2
22. Abdallah HM, Martinez-Meehan D, Lutfi W, et al. Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database. J Thorac Cardiovasc Surg . May 2022;163(5):1669-1681 e3. doi:10.1016/j.jtcvs.2021.01.081
23. Chaft JE, Sima CS, Ginsberg MS, et al. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.J Thorac Oncol . Sep 2012;7(9):1400-5. doi:10.1097/JTO.0b013e3182614856